Flurpiridaz F-18

Drug Profile

Flurpiridaz F-18

Alternative Names: 18F-flurpiridaz; BMS-747158; BMS-747158-02

Latest Information Update: 11 Dec 2015

Price : $50

At a glance

  • Originator Lantheus Medical Imaging
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary artery disease

Most Recent Events

  • 11 Dec 2015 Flurpiridaz F 18 is still in phase III development for Coronary artery disease (Diagnosis) in Finland, Puerto Rico, Canada and USA
  • 30 Sep 2013 Lantheus Medical Imaging completes a phase III trial in Coronary artery disease diagnosis in USA, Canada, Puerto Rico & Finland (NCT01347710)
  • 26 Mar 2013 Lantheus Medical Imaging plans a follow-up phase II trial for Coronary artery disease (diagnosis) in USA (NCT01085162)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top